In an article in last year's Menopause, "Postmenopausal Hormone Therapy And The Risk Of Breast Cancer: A Contrary Thought," (Volume 15, No. 2) Speroff submits that even though "more tumors in hormone users are detected" than in non-hormone users, they are better tumors--"more ductal in situ tumors" and "more node-negative." Moreover, since the cancers might pre-exist, hormone therapy, by accelerating them, could actually have a "beneficial impact, leading to earlier detection." A public service--like AIG's.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
2
1
1
